Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peg-interferon alfa-1b mutant
- Development stage
- Unknown
- Lead developer
- 三元基因
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
peg-interferon alfa-1b mutant is a long-acting, PEGylated recombinant mutant version of interferon alfa-1b, developed by Beijing Tri-Prime Gene Pharmaceutical in collaboration with Beijing Bio-Tech Development. Interferon alfa-1b is a Type I interferon widely used in China for the treatment of viral infections and certain malignancies. This specific mutant version incorporates amino acid substitutions designed to optimize the protein's stability and facilitate site-specific PEGylation. The addition of a polyethylene glycol (PEG) moiety increases the hydrodynamic radius of the molecule, thereby reducing renal clearance and extending its therapeutic half-life. This allows for a more convenient dosing schedule (typically once weekly) compared to non-PEGylated interferons. The drug is primarily being developed for the treatment of chronic hepatitis, aiming to provide sustained viral suppression through its immunomodulatory and direct antiviral activities. It is currently in early-stage clinical development, with Phase 1 trials evaluating its safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
- Other names
- PEG-integrated interferon α1b mutantPEG-integrated interferon mutant injectionPEG-IFN α1b mutantpegylated interferon alfa-1b mutant
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peg-interferon alfa-1b mutant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peg-interferon alfa-1b mutant.